Cancers of unknown primary account for approximately 3% of all new cancer diagnoses, making it one of the 10 most common cancer diagnoses. In a study with extensive investigations, including postmortems, the sites of origin most frequently found were lung, pancreas, colon, kidney, prostate and breast, with no site eventually located in 16% of cases. 1 However routine clinical investigations to demonstrate the organ of origin are less productive, with an approximate 30% rate of identi¢cation which historically has not been associated with signi¢cant impacts on survival.
Overall the outlook for patients with CUP is poor; data from a large modern series demonstrates a median survival of 11 months. 2 However, within these ¢gures are a small proportion who become long-term survivors. These patients almost entirely consist of those with an atypical presentation of a highly treatable malignancy. 3 Fortunately the treatable types of CUP frequently produce serum tumour markers that can be helpful in identifying their origin. The most important diagnoses, in order of bene¢t from treatment, are gestational choriocarcinoma (hCG), germ cell tumours of the testis or ovary (hCG/AFP), prostate cancer (PSA), ovarian cancer (CA 125) and breast cancer (CA 15-3). The belief of clinicians that performing these tests in CUP patients can bring clinical bene¢ts is re£ected in current clinical practice recommendations. The ESMO guidelines recommend that AFP, hCG and PSA should be measured in all men with CUP. 4 Similarly, the American NCCN guidelines recommend these tests and also the use of hCG and AFP in women with mediastinal tumours and CA 125 in women with peritoneal disease or inguinal lymph nodes.
There is little data on the frequency with which tumour marker measurements make an impact on the clinical management of CUP. One recent study from a tertiary referral hospital suggested that less than 1% of tumour marker measurements contributed to making a diagnosis. 5 For a few CUP patients, however, the bene¢ts from a marker-led diagnosis can be signi¢cant. In the trophoblast and germ cell unit at Charing Cross Hospital, we see approximately10 patients a year where the referral has primarily been as a result of elevated markers rather than any other features of CUP.
It is di⁄cult to build an evidence-based case for the routine use of tumour markers in CUP on a few anecdotes, but patients with atypical presentations of potentially curable malignancies do occur and once diagnosed can rapidly achieve a major response to appropriate treatment. The routine testing of the standard tumour markers early on in the workup of all CUP patients would ensure that these relatively rare patients are diagnosed promptly, giving them the optimal chance of receiving e¡ective treatment.
Nevertheless, clinicians should be aware of the shortcomings of the use of tumour markers in CUP. In general, 80% of testicular seminoma and 20% of NSGCT are marker negative, 6 and treatable germ cell tumours or poorly di¡erentiated adenocarcinomas can occur that are marker negative. A point of interest is that CUP patients who are hCG/AFP negative but have the characteristic germ cell tumour I(12p) marker chromosome have a 75% response rate to treatment and a high long-term survival rate, 7, 8 and so should receive prompt treatment with platinum-based chemotherapy. In addition, tumour markers can give false positives as well as false negatives for treatable CUP. Both CEA and CA 125 can be raised for multiple nonmalignancy related reasons and elevated values should be interpreted with caution in the work up of patients who are unwell but without an established diagnosis of malignancy. 9 Alongside the commonly used tumour markers there are a variety of other markers --including CEA, CA 19-9, CA 242 and CA 72-4 --that have varying degrees of speci¢city for other tumours, primarily of gastrointestinal origin. These markers may be used to follow the response to treatment of an established diagnosis although there is no consensus on their value in this situation. 10 With regard to their role in patients with CUP, there is little expert guidance on this and a number of small studies do not show any real bene¢t. 11, 12 What recommendations should be made regarding the use of tumour markers in the investigation of patients with CUP? At present the most important aim is to avoid missing a treatable malignancy. As medical investigations generally proceed in parallel rather than r 2006 The Association for Clinical Biochemistry stepwise, it would be prudent that all patients with CUP have a basic panel of hCG, AFP, PSA, CA 125 and CA 15-3 performed. While the late pick up rate will be low, it will ensure that the majority of patients with a treatable malignancy are identi¢ed. Additionally, clinicians should involve their oncology colleagues at an early point, as they should be familiar with the clinical presentations of some of the treatable, marker-negative types of CUP. These would include squamous cell carcinoma involving the cervical lymph nodes, women with axillary lymphadenopathy and patients with poorly di¡erentiated adenocarcinomas that are likely to respond to therapeutic intervention despite not producing tumour markers.
The role of the second layer of markers (CEA, CA 19-9, CA 242 and CA 72-4) is less clear-cut. While they may be helpful in suggesting a likely source of the malignancy, the level of speci¢city is rarely helpful in guiding treatment for a group of diagnoses largely resistant to systemic therapies. The role of these secondary markers is now also questioned by the availability of newer methods to elucidate the origin of CUP. Molecular genetic analysis using DNA microarray analysis can give 90% accuracy in identifying the origin of tumours. 13 At present this technology is not widely available within routine medical practice, but it may become increasingly used as costs fall --particularly when data showing clinical bene¢ts becomes available.
In summary, the use of the routine markers hCG, AFP, PSA, CA 125 and CA 15-3 in all patients with CUP will ensure that the large majority of highly treatable malignancies are diagnosed. These tests should form part of the initial work up of new CUP patients and should be combined with standard imaging techniques and early involvement of the oncology team. The use of the second level of markers is less well established and at present delivers little extra clinically useful information. New technology examining microarray analysis may well be more helpful in determining the organ of origin of many patients but it is currently unclear whether this information will translate into signi¢cant therapeutic bene¢ts.
